Dr Abedi’s investment in Cytodyn may well transcend the potential utility of Leronlimab to treat GVHD related to a bone marrow transplant; as a hematology oncologist he would also be intimate with CAR-T therapy for some of the hematological cancers such as multiple myeloma with failed chemo regimens…one of the significant complications from CAR-T infusion is CRS (cytokine release syndrome). With CRS, which can be attended by neurotoxicity and organ damage, there is a need for a multi-pronged approach to tamp down the immune system related to specific cytokines (IL-6, IL-10, TNF-α etc)…steroids, tocilizumab for IL6 etc. This should be very familiar to those of us who have followed Leronlimab for severe/critical covid19. Dr Abedi’s investment comes from an interest in making some money from the opportunity he has recognized but likely comes from a real humanitarian impulse to further a really effective treatment for GVHD or CRS; both of these complications can and have resulted in death.